Clinical trials for Neuroblastoma
100 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida · PI: Jordan Milner, MD
- RECRUITINGPhase 1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute · PI: Holly Meany, MD
- RECRUITINGPhase 2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital · PI: Sara Federico, MD
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPhase 1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI) · PI: Hong Ha Rosa Nguyen, M.D.
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona · PI: Charles Hsu, MD
- RECRUITINGPhase 1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University · PI: Katherine Ryan, DO
- RECRUITINGEarly Phase 1NCT07067346Safety & Efficacy of IR-101 in Relapsed/Refractory NeuroblastomaSichuan University · PI: Rong Tian, MD
- RECRUITINGPhase 1NCT07027748Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory NeuroblastomaSteven DuBois, MD · PI: Steven DuBois, MD, MS
- RECRUITINGPhase 1NCT07007117PHOX2B PC-CAR T Cells for Relapsed NeuroblastomaStephan Grupp MD PhD · PI: Jacquelyn Crane, MD
- RECRUITINGPhase 2NCT06933394Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M NeuroblastomaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- RECRUITINGN/ANCT06831552Resource Intervention to Support Equity (RISE) in High-Risk NeuroblastomaDana-Farber Cancer Institute · PI: Kira Bona, MD, MPH
- RECRUITINGPhase 2NCT07100704Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of NivolumabNational Cancer Center Hospital East
- ACTIVE NOT RECRUITINGNCT07278674Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma（CSHEIN）Shanghai Children's Hospital · PI: Jingbo Shao, PhD，chief physician
- RECRUITINGPHASE1, PHASE2NCT06721689PEEL-224, Vincristine and Temozolomide in Pediatric Solid TumorsTheodore Laetsch · PI: Jacquelyn Crane, MD
- RECRUITINGNCT0685280718F-mFBG PET Imaging in the Evaluation of NeuroblastomaFirst Affiliated Hospital of Zhejiang University
- RECRUITINGNCT07141862Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive MethodUniversity Hospital, Clermont-Ferrand · PI: Florence BRUGNON, MD, PhD, HDR
- RECRUITINGPHASE1, PHASE2NCT06803875Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk NeuroblastomaRoberto Chiarle · PI: Susanne Baumeister, MD
- RECRUITINGPhase 1NCT06485947Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in NeuroblastomaPrincess Maxima Center for Pediatric Oncology · PI: Holger Lode, MD, PhD
- RECRUITINGNCT06674811Biomarkers of Resiliency In Childhood Cancer SurgeryMayo Clinic · PI: Stephanie Polites, M.D., M.P.H.
- RECRUITINGPhase 1NCT06751134Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory NeuroblastomaNanjing Children's Hospital
- RECRUITINGNCT07195500Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/ParagangliomaNanjing First Hospital, Nanjing Medical University · PI: Guoqiang Shao, Dr
- RECRUITINGPhase 2NCT06450041NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialNew Approaches to Neuroblastoma Therapy Consortium · PI: Keri Streby, MD
- RECRUITINGPHASE1, PHASE2NCT06836505Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.Sun Yat-Sen University Cancer Center · PI: Yizhuo Zhang
- RECRUITINGPhase 2NCT06540963Tipifarnib and Naxitamab for Relapsed/Refractory NeuroblastomaGiselle Sholler · PI: Valerie Brown, MD, PhD
- ENROLLING BY INVITATIONNCT06703944Risk Model for Metastasis Detection of NeuroblastomaXinhua Hospital, Shanghai Jiao Tong University School of Medicine · PI: juan ma, Doctor
- RECRUITINGEarly Phase 1NCT06684639A Study on the Efficacy of GD2-CAR T Cells in the Treatment of NeuroblastomaThe General Hospital of Western Theater Command · PI: Hai Yi, Ph.D
- RECRUITINGPHASE2, PHASE3NCT06988475DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET DysregulationsCancer Research UK · PI: Matthew Krebs, Dr
- RECRUITINGPHASE1, PHASE2NCT07334301A Multi-Arm, Platform Trial For Relapsed NeuroblastomaUniversity of Birmingham
- RECRUITINGPhase 1NCT06674265Safety and Efficacy of Systemic Allogenic NK Cells in R/R NeuroblastomaMarzieh Ebrahimi · PI: Dr. Marzieh Ebrahimi, PhD. in Medical Immunology
- RECRUITINGPhase 1NCT06631391Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.Sun Yat-sen University · PI: Yizhuo Zhang
- RECRUITINGNCT06480526Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma SurvivorsSt. Jude Children's Research Hospital · PI: Sara Federico, MD
- RECRUITINGPhase 2NCT06607692Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).Fundación de investigación HM · PI: Marta Osuna Marco, PhD
- RECRUITINGPhase 2NCT06528496N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaMemorial Sloan Kettering Cancer Center · PI: Brian Kushner, MD
- RECRUITINGPhase 1NCT06500819Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid TumorsCrystal Mackall, MD · PI: Sneha Ramakrishna, MD
- RECRUITINGN/ANCT06818916Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With NeuroblastomaBeijing Children's Hospital
- RECRUITINGNCT06574698Adding Of Naxitamb In Induction Therapy For High Risk NeuroblastomaGuangzhou Women and Children's Medical Center
- ACTIVE NOT RECRUITINGPhase 1NCT05990751Multi-modular Chimeric Antigen Receptor Targeting GD2 in NeuroblastomaUniversity College, London
- RECRUITINGPhase 2NCT06255210Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)Hongmeng Yu · PI: Hongmeng Yu, Prof.
- RECRUITINGPhase 1NCT05400603Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed OsteosarcomaEmory University · PI: Kelly Goldsmith, MD
- RECRUITINGPhase 2NCT06057948A Study of a Vaccine in Combination With Beta-glucan in People With NeuroblastomaMemorial Sloan Kettering Cancer Center · PI: Brian Kushner, MD
- RECRUITINGN/ANCT06000787MCT for the Harvard/UCSF ROBIN CenterBrigham and Women's Hospital · PI: David Kozono, MD, PhD
- RECRUITINGPHASE1, PHASE2NCT05642455SPEARHEAD-3 Pediatric StudyUSWM CT, LLC · PI: Fiorella Iglesias Cardenas, MD
- RECRUITINGPhase 2NCT06013618Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed NeuroblastomaSun Yat-Sen University Cancer Center · PI: Yizhuo Zhang
- RECRUITINGPhase 1NCT05650749GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic RetinoblastomaStephan Grupp MD PhD · PI: Lisa Wray, MD
- RECRUITINGPhase 1NCT03966651A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.Institut Claudius Regaud
- RECRUITINGPhase 1NCT05701306APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid TumorsAscentage Pharma Group Inc. · PI: Yizhuo Zhang
- RECRUITINGPhase 1NCT05562024TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory NeuroblastomaPersonGen BioTherapeutics (Suzhou) Co., Ltd. · PI: Qiang Zhao, Doctor
- ACTIVE NOT RECRUITINGPhase 1NCT05421897Rapid Administration Pilot for Infusing DinutuximabChildren's Hospital Los Angeles · PI: Sara-Jane Onyeama, MD
- RECRUITINGPhase 1NCT05608148Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid TumorsKyushu University
- RECRUITINGPhase 2NCT05489887Naxitamab Added to Induction for Newly Diagnosed High-Risk NeuroblastomaGiselle Sholler · PI: Jaqueline Kraveka, DO
- RECRUITINGPHASE1, PHASE2NCT04211675NK Cells Infusions With Irinotecan, Temozolomide, and DinutuximabNationwide Children's Hospital · PI: Mark Ranalli, MD
- RECRUITINGPhase 2NCT05135975A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid TumorsNationwide Children's Hospital · PI: Nilay Shah, MD
- RECRUITINGNCT07064746Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of NeuroblastomaNanjing First Hospital, Nanjing Medical University · PI: Guoqiang Shao, Dr
- RECRUITINGPhase 1NCT04897321B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)St. Jude Children's Research Hospital · PI: Chris DeRenzo, MD
- RECRUITINGN/ANCT0582615818F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With NeuroblastomaRigshospitalet, Denmark · PI: Lise Borgwardt, MD, PhD.
- RECRUITINGNCT07516678Serial ctDNA and Molecular Residual Disease Monitoring in NeuroblastomaSun Yat-sen University
- RECRUITINGPhase 2NCT05754684Quadruple Immunotherapy for NeuroblastomaHong Kong Children's Hospital · PI: Daniel Cheuk
- RECRUITINGPhase 1NCT05272371Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive DiseaseJagiellonian University · PI: Walentyna Balwierz, Prof.
- ACTIVE NOT RECRUITINGPhase 1NCT04837547PEACH TRIAL- Precision Medicine and Adoptive Cellular TherapyUniversity of Florida · PI: Giselle Sholler, MD
- RECRUITINGEarly Phase 1NCT0506922018F-MFBG PET/CT in the Evaluation of Neural Crest TumorPeking Union Medical College Hospital · PI: Fang Li
- RECRUITINGPHASE1, PHASE2NCT05027386Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.Sun Yat-sen University · PI: Yizhuo Zhang
- RECRUITINGPhase 2NCT04936529A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With NeuroblastomaMemorial Sloan Kettering Cancer Center · PI: Brian Kushner, MD
- ACTIVE NOT RECRUITINGEarly Phase 1NCT04947501A Study of N9 Chemotherapy in Children With NeuroblastomaMemorial Sloan Kettering Cancer Center · PI: Brian Kushner, MD
- RECRUITINGPhase 2NCT04903899177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk NeuroblastomaJakob Stenman · PI: Jakob Stenman, MD PhD
- ACTIVE NOT RECRUITINGPhase 2NCT04320888Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialNational Cancer Institute (NCI) · PI: Andrea T Franson
- RECRUITINGPhase 3NCT0470691018F-DOPA II - PET Imaging OptimizationUniversity of Alberta · PI: Jonathan Abele, MD
- RECRUITINGPhase 2NCT04301843Eflornithine (DFMO) and Etoposide for Relapsed/Refractory NeuroblastomaGiselle Sholler · PI: Giselle Sholler, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04195555Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI) · PI: Elizabeth D Alva
- ACTIVE NOT RECRUITINGPhase 1NCT04106219A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory NeuroblastomaEli Lilly and Company · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
- RECRUITINGPhase 3NCT04221035High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Gustave Roussy, Cancer Campus, Grand Paris · PI: Claudia Pasqualini, MD PhD
- RECRUITINGNCT04253015A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab BetaRECORDATI GROUP · PI: Jose-Luis Garcia
- RECRUITINGNCT04087902Long-Term Longitudinal QoL in Patients Undergoing EEAOhio State University · PI: Kyle Wu, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03794349Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory NeuroblastomaChildren's Oncology Group · PI: Margaret E Macy
- ACTIVE NOT RECRUITINGPhase 1NCT03618381EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsSeattle Children's Hospital · PI: Katie Albert, MD
- ACTIVE NOT RECRUITINGEarly Phase 1NCT0354172018F-Fluorodopamine PET Studies of Neuroblastoma and PheochromocytomaSt. Jude Children's Research Hospital · PI: Barry Shulkin, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03635632C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)Baylor College of Medicine · PI: Bilal Omer, MD
- RECRUITINGPhase 1NCT03721068Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory OsteosarcomaUNC Lineberger Comprehensive Cancer Center · PI: George Hucks, MD
- ACTIVE NOT RECRUITINGPhase 1NCT02573896Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsNew Approaches to Neuroblastoma Therapy Consortium · PI: Araz Marachelian, MD, MS
- ACTIVE NOT RECRUITINGPhase 2NCT03210714Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI) · PI: Alice Lee
- ACTIVE NOT RECRUITINGPhase 1NCT02914405Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory NeuroblastomaUniversity Hospital Southampton NHS Foundation Trust · PI: Juliet Gray
- ACTIVE NOT RECRUITINGN/ANCT03496402Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)Institut Curie · PI: Gudrun SCHLEIERMACHER, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03213652Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI) · PI: Meredith S Irwin
- RECRUITINGPhase 1NCT03294954GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With NeuroblastomaBaylor College of Medicine · PI: Gengwen Tian, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03373097Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid TumorsBambino Gesù Hospital and Research Institute
- ACTIVE NOT RECRUITINGPhase 2NCT03155620Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)National Cancer Institute (NCI) · PI: Donald W Parsons
- ACTIVE NOT RECRUITINGEarly Phase 1NCT03189706Study of Chemoimmunotherapy for High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · PI: Shakeel Modak, MD
- ACTIVE NOT RECRUITINGNCT03057626Late Effects After Treatment in Patients With Previously Diagnosed High-Risk NeuroblastomaChildren's Oncology Group · PI: Tara O Henderson
- RECRUITINGPhase 1NCT04308330Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS MalignanciesNew York Medical College · PI: Jeremy Rosenblum, MD
- ACTIVE NOT RECRUITINGNCT02868268Neuroblastoma Precision TrialNew Approaches to Neuroblastoma Therapy Consortium · PI: Shahab Asgharzadeh, MD
- RECRUITINGPhase 2NCT02605421Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk NeuroblastomaMasonic Cancer Center, University of Minnesota · PI: Ashish Gupta, MBBS, MPH
- RECRUITINGPhase 2NCT02679144Neuroblastoma Maintenance Therapy TrialGiselle Sholler · PI: Giselle Sholler, MD
- RECRUITINGNCT03568669Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS)Debra Weese-Mayer
- ACTIVE NOT RECRUITINGPhase 1NCT02298348Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaNew Approaches to Neuroblastoma Therapy Consortium
- RECRUITINGPhase 2NCT02559778Pediatric Precision Laboratory Advanced Neuroblastoma TherapyGiselle Sholler · PI: Giselle Sholler, MD
- ACTIVE NOT RECRUITINGN/ANCT02307630PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot StudyMemorial Sloan Kettering Cancer Center · PI: Shakeel Modak, MD
- ACTIVE NOT RECRUITINGPhase 1NCT01953900iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and NeuroblastomaBaylor College of Medicine · PI: Lisa L Wang, MD
- ACTIVE NOT RECRUITINGPhase 1NCT018226523rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAINBaylor College of Medicine · PI: Andras A. Heczey, MD
- ACTIVE NOT RECRUITINGPhase 2NCT01857934Therapy for Children With Advanced Stage NeuroblastomaSt. Jude Children's Research Hospital · PI: Sara M. Federico, MD